Previous close | 1.1600 |
Open | 1.1600 |
Bid | 1.1100 x 400 |
Ask | 1.1600 x 400 |
Day's range | 1.0800 - 1.1600 |
52-week range | 0.5400 - 6.2600 |
Volume | |
Avg. volume | 4,471,001 |
Market cap | 173.66M |
Beta (5Y monthly) | 2.25 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.8900 |
Earnings date | 07 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 7.22 |
CAMBRIDGE, Mass., May 06, 2024--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 8, 2024 at 8:30 a.m. ET to discuss first quarter 2024 financial results and provide business updates.
CAMBRIDGE, Mass., April 09, 2024--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that enrollment is complete in the placebo-controlled Cohort 2 of its Phase 1b trial of SER-155 in patients who received Allogeneic Hematopoietic Stem Cell Transplantation (Allo HSCT). SER-155 is an orally administered, consortium of bacteria, cultivated from cell banks and designed to reduce the incidence and severity of enteric-derived infections and resulting b
Key Insights Seres Therapeutics' Annual General Meeting to take place on 4th of April CEO Eric Shaff's total...